Isoflurane intravenous - Yichang Humanwell Pharmaceutical

Drug Profile

Isoflurane intravenous - Yichang Humanwell Pharmaceutical

Alternative Names: emulsified isoflurane - Yichang Humanwell Pharmaceutical

Latest Information Update: 28 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Yichang Humanwell Pharmaceutical
  • Developer West China Hospital Sichuan University; Yichang Humanwell Pharmaceutical
  • Class General anaesthetics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Anaesthesia

Most Recent Events

  • 27 Jul 2017 Phase-II clinical trials in Anaesthesia in China (Inhalation) before July 2017 (ChiCTR-IIR17012142)
  • 27 Jul 2017 Phase-II clinical trials in Anaesthesia in China (IV) before July 2017 (ChiCTR-IIR17012142)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top